Restoration of Striatal Neuroprotective Pathways by Kinase Inhibitor Treatment of Parkinson’S Disease-Linked LRRK2-Mutant Mice

Researchers tested the leucine-rich repeat kinase 2 (LRRK2) inhibitor MLi-2 in a mouse model of early stage, LRRK2 mutation–associated Parkinson’s disease.